Cargando…

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

OBJECTIVE—The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy. RESEARCH DESIGN AND METHODS—In this 26-week, doubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauck, Michael, Frid, Anders, Hermansen, Kjeld, Shah, Nalini S., Tankova, Tsvetalina, Mitha, Ismail H., Zdravkovic, Milan, Düring, Maria, Matthews, David R.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606836/
https://www.ncbi.nlm.nih.gov/pubmed/18931095
http://dx.doi.org/10.2337/dc08-1355
_version_ 1782162992530456576
author Nauck, Michael
Frid, Anders
Hermansen, Kjeld
Shah, Nalini S.
Tankova, Tsvetalina
Mitha, Ismail H.
Zdravkovic, Milan
Düring, Maria
Matthews, David R.
author_facet Nauck, Michael
Frid, Anders
Hermansen, Kjeld
Shah, Nalini S.
Tankova, Tsvetalina
Mitha, Ismail H.
Zdravkovic, Milan
Düring, Maria
Matthews, David R.
author_sort Nauck, Michael
collection PubMed
description OBJECTIVE—The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy. RESEARCH DESIGN AND METHODS—In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments were in combination therapy with metformin (1g twice daily). Enrolled subjects (aged 25–79 years) had type 2 diabetes, A1C of 7–11% (previous OAD monotherapy for ≥3 months) or 7–10% (previous OAD combination therapy for ≥3 months), and BMI ≤40 kg/m(2). RESULTS—A1C values were significantly reduced in all liraglutide groups versus the placebo group (P < 0.0001) with mean decreases of 1.0% for 1.8 mg liraglutide, 1.2 mg liraglutide, and glimepiride and 0.7% for 0.6 mg liraglutide and an increase of 0.1% for placebo. Body weight decreased in all liraglutide groups (1.8–2.8 kg) compared with an increase in the glimepiride group (1.0 kg; P < 0.0001). The incidence of minor hypoglycemia with liraglutide (∼3%) was comparable to that with placebo but less than that with glimepiride (17%; P < 0.001). Nausea was reported by 11–19% of the liraglutide-treated subjects versus 3–4% in the placebo and glimepiride groups. The incidence of nausea declined over time. CONCLUSIONS—In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin.
format Text
id pubmed-2606836
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-26068362010-01-01 Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study Nauck, Michael Frid, Anders Hermansen, Kjeld Shah, Nalini S. Tankova, Tsvetalina Mitha, Ismail H. Zdravkovic, Milan Düring, Maria Matthews, David R. Diabetes Care Emerging Treatments and Technologies OBJECTIVE—The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy. RESEARCH DESIGN AND METHODS—In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments were in combination therapy with metformin (1g twice daily). Enrolled subjects (aged 25–79 years) had type 2 diabetes, A1C of 7–11% (previous OAD monotherapy for ≥3 months) or 7–10% (previous OAD combination therapy for ≥3 months), and BMI ≤40 kg/m(2). RESULTS—A1C values were significantly reduced in all liraglutide groups versus the placebo group (P < 0.0001) with mean decreases of 1.0% for 1.8 mg liraglutide, 1.2 mg liraglutide, and glimepiride and 0.7% for 0.6 mg liraglutide and an increase of 0.1% for placebo. Body weight decreased in all liraglutide groups (1.8–2.8 kg) compared with an increase in the glimepiride group (1.0 kg; P < 0.0001). The incidence of minor hypoglycemia with liraglutide (∼3%) was comparable to that with placebo but less than that with glimepiride (17%; P < 0.001). Nausea was reported by 11–19% of the liraglutide-treated subjects versus 3–4% in the placebo and glimepiride groups. The incidence of nausea declined over time. CONCLUSIONS—In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin. American Diabetes Association 2009-01 /pmc/articles/PMC2606836/ /pubmed/18931095 http://dx.doi.org/10.2337/dc08-1355 Text en Copyright © 2009, American Diabetes Association https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Emerging Treatments and Technologies
Nauck, Michael
Frid, Anders
Hermansen, Kjeld
Shah, Nalini S.
Tankova, Tsvetalina
Mitha, Ismail H.
Zdravkovic, Milan
Düring, Maria
Matthews, David R.
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
title Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
title_full Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
title_fullStr Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
title_full_unstemmed Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
title_short Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
title_sort efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the lead (liraglutide effect and action in diabetes)-2 study
topic Emerging Treatments and Technologies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606836/
https://www.ncbi.nlm.nih.gov/pubmed/18931095
http://dx.doi.org/10.2337/dc08-1355
work_keys_str_mv AT nauckmichael efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT fridanders efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT hermansenkjeld efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT shahnalinis efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT tankovatsvetalina efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT mithaismailh efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT zdravkovicmilan efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT duringmaria efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT matthewsdavidr efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study
AT efficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetestheleadliraglutideeffectandactionindiabetes2study